A股異動丨上海萊士大漲8.88% 收到上海市經信委關於《生產能力應急徵用通知》
格隆匯2月5日丨上海萊士(002252.SZ)大漲8.88%,報8.95元,總市值445.23億元。2月4日晚間,上海萊士公告稱,2月3日,公司收到上海市經濟和信息化委員會關於《生產能力應急徵用通知》。通知顯示,“緊急徵用貴單位的醫療防護用品、藥品、器械及生產能力。自本通知印發之日起,貴單位需全力做好原材料、人員的調配,所生產的涉及疫情防控的物資需經我委同意後向市場供給。對因此給貴單位造成經濟損失的,我們將依法予以合理補償。”上海萊士的主營業務為生產和銷售血液製品,主要產品為人血白蛋白、靜注人免疫球蛋白、特免類、凝血因子類產品等,是目前中國最大的血液製品生產企業之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.